Linfomas
GLUN
Hospital Universitario Virgen del Rocío
Sevilla, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Virgen del Rocío (11)
2024
-
Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell-like Type: Phase II Clinical Trial of the Spanish GELTAMO Group
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 17, pp. 3704-3714
2023
-
Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)
Journal of Clinical Medicine, Vol. 12, Núm. 20
2022
-
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 1, pp. 24-33
-
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 7, pp. 483-494
-
The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study
Cancers, Vol. 14, Núm. 3
2021
-
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma
Blood, Vol. 137, Núm. 1, pp. 49-60
-
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma
Future Oncology, Vol. 17, Núm. 11, pp. 1295-1310
-
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
Journal of Hematology and Oncology
2020
-
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
The Lancet Haematology, Vol. 7, Núm. 7, pp. e511-e522
2012
-
Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series
Leukemia and Lymphoma, Vol. 53, Núm. 5, pp. 812-819
2010
-
Amolecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma
Blood, Vol. 116, Núm. 8